Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress

Core Insights - Corbus Pharmaceuticals Holdings Inc. announced that an abstract on updated clinical data for CRB-701 has been accepted for presentation at the ESMO Congress 2025 in Berlin, scheduled for October 17-21, 2025 [1][2] Company Overview - Corbus Pharmaceuticals is a clinical-stage company focused on oncology and obesity, aiming to develop innovative scientific approaches to combat serious illnesses [5] - The company's pipeline includes CRB-701, an antibody-drug conjugate targeting Nectin-4, CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor inverse agonist for obesity treatment [5] Clinical Study Details - The Phase 1/2 study (NCT06265727) of CRB-701 is evaluating safety, pharmacokinetics, and efficacy in patients with advanced solid tumors expressing high levels of Nectin-4 [3] - The study consists of three parts: Part A (dose escalation), Part B (dose optimization), and Part C (dose expansion), with ongoing dose optimization at 2.7 mg/kg and 3.6 mg/kg cohorts [3] - The company expects to complete dose optimization and identify a recommended Phase 2 dose by Q4 2025 [3] Product Information - CRB-701 is a next-generation antibody-drug conjugate that targets Nectin-4, utilizing a site-specific, cleavable linker and a drug antibody ratio of 2, with MMAE as the cytotoxic payload [4] - Nectin-4 is recognized as a clinically validated tumor-associated antigen in urothelial cancer [4]